Gene-editing drug lowers bad cholesterol

A new gene-editing therapy shows early promise in lowering bad cholesterol with a single dose, marking a potential milestone for long-term treatment.

An experimental gene-editing drug called VERVE-102 has shown positive initial results in a Phase I clinical trial. The study, involving a small group of patients, tested the safety of a single infusion designed to permanently lower LDL, or "bad," cholesterol. Interim results published in a medical journal indicated a significant reduction in cholesterol levels, with some patients seeing a drop of up to 62%. The therapy works by making a precise change to a gene in the liver that controls cholesterol production. This one-time treatment is being developed as a potential long-term alternative to daily medications for individuals with a genetic predisposition to high cholesterol.

This development is a significant milestone for in vivo gene-editing, where genetic modifications are made directly inside the body. For the tech and business community, it highlights the rapid maturation of CRISPR-based technologies from laboratory concepts into practical therapeutic applications. The success of such a trial could pave the way for a new class of "one-and-done" treatments for a wide range of chronic diseases, fundamentally changing pharmaceutical business models. This represents a major advance in deep tech, signaling new investment and innovation opportunities at the intersection of biotechnology and data science.

This is a significant milestone for in vivo gene-editing, demonstrating that complex biological programming is becoming a practical reality. It signals a potential shift towards 'one-and-done' treatments for chronic diseases, creating new opportunities at the intersection of biotech and data science.

The success of single-dose gene therapies could disrupt the pharmaceutical industry's reliance on daily medications for chronic conditions. For tech investors and founders, it highlights a maturing deep tech sector with significant long-term potential, particularly in biotech and personalized medicine.